We were able to facilitate plasminogen activator inhibitor 1 
Introduction
Regulation of blood coagulation and fibrinolysis by vascular endothelial cells is a key process that maintains the integrity of the circulation in large vessels, as well as in the microvascular system. Thrombomodulin (TM), a membrane-bound glycoprotein of vascular endothelial cells, binds to thrombin and alters the enzyme specificity of thrombin. Upon binding to TM, thrombin loses its clotting activity and gains the ability to activate protein C. Thus, TM works as an important regulator of blood coagulation (see review, Ref. 1). In mice, TM deficiency is embryonic lethal, suggesting that loss of TM expression in the vascular system leads to thrombus formation and subsequent defects in the vasculature. 2 TM gene expression is down-regulated by inflammatory cytokines, bacterial endotoxins, 1, [3] [4] [5] and transforming growth factor β1 (TGFβ1). 6 In particular, inflammatory cytokines and endotoxins induce expression of procoagulant tissue factor in endothelial cells and monocytes/macrophages, and down-regulate TM gene expression in endothelial cells resulting in a thrombotic state. 1 Plasminogen activator inhibitor 1 (PAI-1), the physiological inhibitor of both tissue-type plasminogen activator and urokinase-type plasminogen activator, is secreted from vascular endothelial cells and plays a role as a primary regulator of vascular thromobolysis. 7 PAI-1 gene expression is dramatically up-regulated by inflammatory cytokines, TNFα, TGFβ1, and bacterial endotoxins. 7 Thus, TNFα released from monocytes/ macrophages, bacterial endotoxins and/or TGFβ1 released from endothelial cells and platelets may decrease TM expression and up-regulate PAI-1 and tissue factor expression. This may lead to hypercoagulable and hypofibrinolytic states in bacterial infections, especially sepsis, and thrombotic events. Although TM is widely expressed in vascular endothelial cells, 8 brain TM expression has been shown to be significantly decreased in the pons, the mid-brain, and the putamen. 9 Decreased BCEs were transfected with plasmids pPAI-1/luc, pCEP/luc and pCAG/luc in the absence or presence of TGFβ1 (1 ng/ml) or of TNFα (10 ng/ml) to determine the effects of TGFβ1 and TNFα on promoter activities, and luciferase activities in the cell lysate were quantified as in Methods. Promoter activities of each promoter were significantly increased in the presence of TGFβ1 (1 ng/ml) (*P Ͻ 0.05; **P Ͻ 0.01, n = 4). Activities of PAI-1 and CEP promoters was increased in the presence TNFα (10 ng/ml) (*P Ͻ 0.05; **P Ͻ 0.01, n = 4). Decrease of CAG promoter activity in the presence of TNFα (10 ng/ml) was not statistically significant. There was no significant difference between CEP promoter activity in the presence of TGFβ1 (1 ng/ml) and CAG promoter activity in the presence of TGFβ1 (1 ng/ml).
expression of TM is assumed to be one of the reasons for a high incidence of cerebral thrombosis in these regions.
Transfer and high expression of the TM gene in vascular endothelial cells during decreased endogenous TM expression in pathological conditions may be a logical approach to preventing obstruction of blood vessels by thrombus formation and to maintain the integrity of the circulation. While transfer of genes to cells is achieved by a variety of in vitro methods, recombinant viral vectors are used mainly to transduce cells in vivo for gene therapy. Among viral vectors, recombinant adeno-associated virus (rAAV) vectors are preferred, because it is possible to transfer genes to nondividing cells, long-term expression of transgenes is achieved, and no pathological effects of wildtype AAV have been reported. Another attractive feature of rAAV is their low immunogenecity (see reviews, Refs 10-12). A variety types of cultured cells [10] [11] [12] including vascular smooth muscle cells 13 could be transduced by rAAV vectors in vitro. Therefore, we constructed rAAV vectors which contained the human TM gene driven by the enhanced PAI-1 promoter for transduction of vascular endothelial cells for thrombomodulin transgene expression in vitro and in vivo.
Results

Activities and properties of enhanced PAI-1 promoter
We used the DNA fragment (Ϫ800 to +76) of the 5' flanking region of PAI-1 gene in our experiments. This fragment has been shown to contain regulatory elements, the TATA box, the transcription initiation site, and a part of exon I of the PAI-1 gene, as well as the TGFβ1 responsive sequences. [14] [15] [16] [17] To evaluate the PAI-1 promoter activity and to explore the possibility of enhancing its promoter activity, we studied the activities of the PAI-1 promoter and the enhanced PAI-1 (CEP) promoter in comparison with the activity of the CAG promoter using the luciferase gene as a reporter. The CAG promoter, which consists of CMV enhancer, chicken β actin promoter, and a growth factor intron, is one of the strongest promoters 18 and is utilized to express genes in mammalian cells by plasmid vectors, as well as by viral vectors. As shown in Table 1 , PAI-1 promoter activity was approximately 5% of the CAG Gene Therapy promoter activity, while the CEP promoter activity was approximately 67% of the CAG promoter activity. In the presence of TGFβ1 (1 ng/ml), the CEP promoter activity increased approximately two-fold and this activity was even higher than CAG promoter activity in the absence of TGFβ1 and nearly the same as that of CAG promoter activity in the presence of TGFβ1. PAI-1 promoter activity has been shown to be increased by several to 50-fold in the presence of TGFβ1, [15] [16] [17] however, enhancement of PAI-1 promoter activity by TGFβ1 in our system was approximately three-fold. These discrepancies may be caused by the differences in cell lines used for the assay. In fact, when we used Mlv1 Lu cells to study the effect of TGFβ1 on PAI-1 promoter, PAI-1 promoter activity increased in the presence of TGFβ1 by 10-fold (not shown). Addition of TNFα also increased the PAI-1 promoter activity approximately two-fold and the CEP promoter activity by 29%. PAI-1 or CEP promoter activity did not increase in response to TNFα to levels as high as those reported previously. 19, 20 These observations may be explained by the possibility that DNA fragments used in this study may lack the TNFα responsive elements located upstream of the fragment, although one TNFα responsive element does reside in this fragment. 21, 22 Based upon data shown in Table 1 , the CEP promoter appeared to be 14-fold stronger than the PAI-1 promoter, comparable to the CAG promoter, and had similar responses to TGFβ1 and TNFα with the PAI-1 promoter.
Construction of rAAV2 vectors
In order to develop recombinant virus vectors to transfer genes into vascular endothelial cells, we constructed rAAV2 vectors using the PAI-1 promoter, the enhanced PAI-1 (CEP) promoter, and the CAG promoter as shown in Figure 1 and attempted to transduce vascular endothelial cells to express the TM gene. Because effects of cytokines and TGFβ1 on PAI-1 gene expression are contrary to those on TM gene expression, use of the enhanced PAI-1 promoter may be ideal for expressing TM in the vascular endothelial cells in a specific and timely manner, and rAAV2 vectors may be preferred for transferring genes in vivo. rAAV2/PTIG, rAAV2/CEPT, and rAAV2/CAGT were designed to express the TM cDNA driven by the PAI-1 promoter, CEP promoter, and CAG promoter, respectively. To co-express the GFP reporter gene, the IRES and the GFP gene sequences were cloned downstream of the TM cDNA sequence in rAAV2/PTIG and rAAV2/CEPTIG as shown in Figure 1 .
Expression of human TM and GFP in endothelial cells transduced by rAAV2 vectors rAAV2/PTIG or rAAV2/CEPTIG
To see if rAAV2 vectors could transduce vascular endothelial cells, several types of cultured vascular endothelial cells were incubated in media in the presence of rAAV2 vectors, rAAV2/PTIG, rAAV2/CEPTIG, or rAAV2/lacZ and the expression of TM, GFP, or β-galactosidase in cultured vascular endothelial cells was studied ( Figure 2 ). rAAV2 vectors were able to transduce bovine capillary endothelial cells (BCE; Figure 2 ) and bovine pulmonary artery endothelial cells (CPAE; Figure 2 ). The arrow indicated the immunopositive cell for human TM, whereas the neighboring cell was negative for immunostaining in Figure 2e . Among the endothelial cells tested, AAV2 vectors could transduce BCEs most efficiently. After transduction of BCEs by rAAV2/PTIG, we analyzed expression of GFP by FACS to determine transduction efficiency. At an MOI of 2 × 10 4 , 14.7% of BCEs expressed GFP. rAAV2 vectors also could transduce bovine brain microcapillary endothelial cells (BBME), bovine pulmonary microvascular endothelial cells (BPME), and bovine aortic endothelial cells (BAE) (not shown). However, BBME and BPME were transduced by rAAV2 vectors less efficiently than BCE. The transduction efficiency of BAEs by the rAAV vectors was much less than that of other endothelial cell types. rAAV2 vectors could not transduce human umbilical vein endothelial cells (HUVECs). These differences in the transduction efficiency of recombinant AAV2 vectors may be due to differences in the expression
Figure 2 Expression of human TM and GFP in BCEs or CPAEs transduced by rAAV2 vectors rAAV2/PTIG, rAAV2/CEPTIG, rAAV2/CEPT, or rAAV2/lacZ. Cultured cells were incubated in the presence of rAAV2 vectors for 72 h and human TM and GFP were detected by immunohistochemistry and fluorescent microscopy, respectively. Immunohistochemical studies for detection of recombinant human TM expressed in CPAEs incubated with rAAV2/PTIG (a) or rAAV2/CEPTIG (c) and fluorescent microscopic examination of CPAEs for detection of GFP expression incubated in the presence of rAAV2/PTIG (b) or rAAV2/CEPTIG (d) are shown. Distinctive cell shapes permitted detection of both TM and GFP in the same cell. Arrows indicate immunopositive cells (immunostainingnegative and fluorescent-negative cells were also present beside transduced cells in panel c, but they were not visible in the photograph because no nuclear staining was performed). Similarly, rAAV2/CEPT-transduced BCEs (e) were investigated for TM expression by immunohistochemistry. The arrow indicated an immunopositive cell, whereas the neighboring cell was negative for immunostaining, but was visualized by nuclear staining (e). rAAV2/lacZ-transduced BCEs were stained with X-gal for ␤-galactosidase expression (f).
of the AAV2 receptor and/or co-receptors in these cells or the phosphorylation state of the single-stranded Dsequence binding protein. [23] [24] [25] [26] When rAAV2/PTIG or rAAV2/CEPTIG were used, the same endothelial cell expressed both TM and GFP (Figure 2 ). These data indicated that these rAAV2 vectors successfully infected the cells and that the PAI-1 and CEP promoters drove expression of the respective genes located downstream.
Quantitative analyses of recombinant human TM expressed in BCEs transduced by rAAV2 vectors
Quantitative analyses of human TM expression in rAAV2 vector-transduced BCEs in vitro were performed and were compared with data of activities of PAI-1, CEP and CAG promoters shown in Table 1 . Monoclonal antibodies used in ELISA or immunohistochemistry did not react with bovine TM, thus the TM molecule detected by ELISA in BCEs infected with rAAV2 vectors was recombinant human TM. Transduction of BCEs was dose-dependent up to MOI of 10 6 and was time-dependent, reaching a plateau after 16 h incubation of BCEs with rAAV2 vectors (Figure 3 ). These data were comparable with previous data. 13 Table 2 shows expression of TM in BCEs transduced by rAAV2/PTIG, rAAV2/CEPT or rAAV2/CAGT vectors. The amount of recombinant human TM expressed in BCEs transduced by rAAV2/PTIG at an MOI of 10 5 was approximately fivefold higher than that of human TM constitutively expressed in cultured HUVECs. When the human TM transgene was driven by the enhanced PAI-1 promoter CEP, the amount of recombinant TM expressed in BCEs incubated with rAAV2/CEPT at MOI of 10 5 was approximately 116-fold higher than in BCE transduced by AAV2/PTIG and 616-fold higher than that of human TM constitutively expressed in HUVECs. In accordance with the data of promoter activity shown in Table 1 , the Gene Therapy amount of human TM expressed in BCEs transduced by rAAV2/CEPT was approximately 42% of that in BCEs transduced by rAAV2/CAGT. Human TM gene expression in BCEs transduced by rAAV2/CEPT was enhanced in the presence of TGFβ1 more than two-fold and this level of TM expression was nearly the same as that in BCEs infected with rAAV2/CAGT and was approximately 1000-fold higher than that in HUVECs. Human TM gene expression in BCEs transduced by rAAV2/CEPT was also enhanced in the presence of TNFα by 1.5-fold. Incubation of BCEs with AAV2/CEPT for 60 min yielded TM expression at the same level as BCE incubated with AAV2/PTIG. This level of TM expression was five-fold higher than that of endogenous TM expression in HUVECs. Overall, these data were consistent with those of the promoter activity analyses shown in Table 1 , but there was discrepancy between data of promoter activity and of TM expression in rAAV2 vector transduced BCEs shown in Tables 1 and 2 . TM expression in rAAV2/PTIG-transduced BCEs was less than 1/100 of that in rAAV2/CEPT-transduced BCEs while PAI-1 promoter activity was 1/20 of that of the CEP promoter. This was most likely caused by coexpression of GFP under the same promoter using IRES. Hence TM expression in BCEs transduced by rAAV2/CEPTIG, in which the CEP promoter drove the TM cDNA and GFP gene using IRES, was decreased approximately 10-fold compared with that in rAAV2/CEPT-transduced BCEs (not shown). Other minor discrepancies may have been caused by differences in incubation time. Accumulation of TM and luciferase molecules in cells may also be different and affect the results.
Expression of human TM in brain vascular endothelial cells of Mongolian gerbils in vivo
To explore the possibility of transducing brain vascular endothelial cells as a gene therapy model, we intravenously injected rAAV2 vectors in Mongolian gerbils. Mongolian gerbils are rodents that have poor anastomoses between the carotid artery system and the vertebral artery system. Since experiments were designed to inject rAAV2 vectors in the common carotid artery of Mongolian gerbils, strong and endothelial cell-specific promoters would be required to express the transgenes in vivo. Because the transduction efficiency of endothelial cells by rAAV2 vectors in vivo was expected to be low due to a short exposure time, the CEP promoter was thought to be suitable for this purpose in terms of its promoter activity and tissue specificity. We injected rAAV2/CEPT into the carotid artery of Mongolian gerbils and looked at the expression of human TM in the brain by immunohistochemistry using human TM specific antibodies on day 7. As shown in Figure 4 , human TM was detected in capillaries of the Mongolian gerbil brain. No significant staining was observed in the neurons or glias. In control animals with buffer injections, no staining was observed in vascular endothelial cells of the brain, the lung or the kidney. These data indicated that the brain vascular endothelial cells of gerbils were transduced by rAAV2 vectors and the CEP promoter drove the human TM transgene in vivo. Amounts of recombinant human TM expressed in BCEs (10 4 cells) incubated in the presence of rAAV2/PT, rAAV2/CEPT, rAAV2/CAGT at 10 5 of MOI for 72 h in the absence or presence of TGFβ1 (1 ng/ml) or TNFα (10 ng/ml) were quantified by an ELISA. Expression of TM in BCEs transduced by each rAAV2 vector was significantly increased in the presence of TGFβ1 (1 ng/ml) (**P Ͻ 0.01, n = 4) and amounts of TM in BCEs transduced by rAAV2/CEPT was also significantly increased in the presence TNFα (10 ng/ml) (**P Ͻ 0.01, n = 4). ND, not determined. 
ml HBS) was injected in the left common carotid artery of two gerbils. Gerbils were anesthetized and killed after irrigation with physiological saline-containing heparin (1 U/ml) followed by 4% paraformaldehyde on day 7. Detection of human thrombomodulin expressed in the brain vascular endothelial cells was carried out by immunohistochemistry using goat polyclonal antibodies to human TM. In panel a, immunostaining was observed in four endothelial cells of tangentially sliced brain capillaries (×100). Immunostaining was also seen in capillaries in the coronal section of a capillary in panel b (×40). A part of the section is shown in panel c at higher magnification (×100). Arrows indicate immunopositive areas. These pictures were derived from two independent gerbils. No immunostaining was observed in vascular endothelial cells of the brain, the lung or the kidney of control gerbils.
Discussion
Recent studies have shown that in many pathological conditions, gene transfer may provide a new approach for the prevention and treatment of a variety of diseases such as hemophilia. [27] [28] [29] Although conventional antithrombotic treatments with antiplatelet and anticoagulant drugs are effective, they are associated with hemorrhagic side-effects, gastric ulcers and intolerance. In addition, thrombotic thrombocytopenic purpura was associated with ticlopidine administration. 30, 31 Thus, sitedirected and vascular cell-oriented gene transfer achieving a long-term expression of anticoalgulant and antiplatelet molecules may be a unique and attractive therapy for vascular diseases. 32 Recombinant viral vectors using viral promoters and strong mammalian gene promoters have been mainly used to express genes in vivo, however, these promoters have no tissue specificity. Moreover, down-regulation of a viral promoter may take place in vivo. 12 For an ideal gene therapy, timely expression of transgenes at the specific site may be required. PAI-1 expression is restricted to vascular cells and adipocytes under physiological conditions 19, 33 and is up-regulated by a variety of molecules including TGFβ1, inflammatory cytokines, and bacterial endotoxins. 7 These properties of the PAI-1 promoter may be well suited to timely expression of anticoagulant molecules, since procoagulant tissue factor expression is induced in endothelial cells and monocytes/ macrophages and TM expression is down-regulated in endothelial cells by endotoxin and inflammatory cytokines. In addition, TGFβ1 production is increased after brain ischemia 34 suggesting that the characteristics of the PAI-1 promoter may be suited to express transgenes in the ischemic state. Unfortunately, the PAI-1 promoter was not as strong as the CAG promoter, but we were successful in facilitating PAI-1 promoter activity using an enhancer element. As shown in Table 1 , the enhanced PAI-1 promoter CEP was nearly as effective as the CAG promoter in terms of basal activity and had a response similar to the PAI-1 promoter with respect to TGFβ1 and TNFα stimulation. Using rAAV2 vectors, the CEP promoter also drove transgenes in rAAV2 vector-transduced endothelial cells (Figure 2) as efficiently as the CAG promoter ( Table 2) . Comparison of TM expression in rAAV2/CEPT-transduced BCEs with constitutive TM expression in HUVECs revealed that expression of the TM from the transgene can be increased to more than 1000-fold higher than that of TM in HUVECs in vitro, suggesting that this vector may be superior for transduction of vascular endothelial cells.
The rAAV2/CEPT vector also could transduce vascular endothelial cells in vivo to express the TM transgene in the brain of Mongolian gerbils. We injected the rAAV2/CEPT vector into the left common carotid artery with temporary clamping of the contralateral carotid artery under anesthesia only for 5 min. Even with this short exposure, this vector could transduce brain endothelial cells. Because no significant immunostaining was detected in control animal specimens by antibodies used in this study, TM molecules detected in Figure 4 should be derived from the transgene. In addition, Gerbil TM in the lung extracts was not detected by the same antibody by Western blotting (not shown). Although human TM expression in gerbils was detected by immunohistochemistry in this study, quantitative evaluation of human TM expression by ELISA or Western blotting was not successful. This may be due to relatively low expression of the human TM compared with other proteins. Thus, we could not determine the reactivity of transgene expression to TGFβ1 or TNFα. We used the human TM gene instead of the rodent TM gene in recombinant AAV2 vectors to detect transgene expression in vivo in this study, otherwise we could not detect transgene expression by antibodies. TM has species specificity in terms of its regulatory activity on blood coagulation because human TM inhibits the thrombin clotting activity approximately 100-fold less effectively than rat TM in rats (unpublished data). Thus human TM may not work efficiently to prevent thrombus formation in rodents. Further studies using rodent TM genes will be undertaken to see if transduction of TM genes into cerebral endothelial cells is effective in preventing thrombus formation resulting in prevention of brain ischemia.
The PAI-1 promoter-based recombinant AAV2 vectors may be useful to transduce vascular endothelial cells not only in the brain, but also in a variety of vessels including the coronary arteries of the heart. In addition to the TM gene, a variety of genes can be expressed in vascular endothelial cells using our system. Since topical administration of rAAV vectors is more effective than an intravenous injection for transduction of cells, [10] [11] [12] transcatheter injection of recombinant AAV vectors at specific sites may be suitable for this purpose. Another clinical application of this system may be ex vivo transduction of vascular endothelial cells of surgically removed vessels, such as the saphenous vein used in coronary artery bypass grafting, to express the TM gene. Although these vessels express TM constitutively, expression of TM in the removed vessels may be increased to the desired level by transient incubation of the vessels with rAAV2/CEPT at an appropriate MOI followed by implantation in vivo. This procedure may increase the efficacy of coronary artery bypass grafts after surgery and such studies are currently in progress.
Materials and methods
Genomic libraries, cloned genes, antibodies
The λDash II phage human genomic library (YG-LI020), established by Sakaki et al (Human Genome Center, InstiGene Therapy tute of Medical Science, Tokyo University, Japan), was kindly supplied by the Japan Health Sciences Foundation Health Science Research Resources Bank. The human PAI-1 gene was isolated from the λDash II phage human genomic library using the human PAI-1 cDNA as a probe and an 876 bp fragment (-800 to +76) was excised from the PAI-1 gene using restriction enzymes HindIII and EcoRI. This fragment has been shown to contain regulatory elements, the TATA box, and the transcription initiation site of the PAI-1 gene.
14 This was designated as the PAI-1 promoter in this study. The human thrombomodulin cDNA and gene were previously described. 35 Monoclonal antibodies and ELISA kits for human TM were kindly provided by Teijin (Tokyo, Japan) and polyclonal antibodies to human TM that did not cross-react to TM of other species, were purchased from American Diagnostica (Greenwich, CT, USA).
Promoter activity assay
The PAI-1 promoter was cloned at the 5' end of the luciferase gene of plasmid pGL3 Basic (Promega, Madison, WI, USA) in the appropriate orientation to make plasmid pPAI-1/luc for the promoter activity assay. The cytomegalovirus (CMV) enhancer fragment, excised from the CMV immediate-early promoter using restriction enzymes SpeI and NcoI, was ligated with the 5' end of the human PAI-1 promoter to see if PAI-1 promoter activity was enhanced and the resultant fragment was termed the enhanced PAI-1 (CEP) promoter. To compare promoter activity of these fragments, the CAG promoter 18 (a generous gift from D Miyazaki, Osaka University, Osaka, Japan) was used as the control promoter in this study. The CEP and CAG promoters excised from pCAGGS were also cloned into pGL3 Basic as described above to make plasmids pCEP/luc and pCAG/luc, respectively. Plasmids pPAI-1/luc, pCEP/luc, and pCAG/luc were purified using QIAGEN plasmid kits (Qiagen Japan, Tokyo, Japan). Bovine microvascular endothelial cells derived from adrenal glands seeded in 96-well culture plates were incubated in serum-free media in the presence of plasmid DNA (0.1 g/well) and LipofectAMINE Plus (GIBCO BRL, Life Technologies, MD, USA) for 3 h. Cells were washed with and incubated in media containing FBS (10%). After 3 h incubation, cells were washed and further incubated in medium containing FBS (1%) for 20 h in the absence or presence of TGFβ1 (1 ng/ml). Luciferase activities in cell lysates were quantified using the Steady-Glo luciferase assay system (Promega) and a Luminometer TopCount (Packard, Meriden, CT, USA) according to the manufacturer's instructions.
Construction of plasmid vectors
Four types of AAV vectors were constructed to express human TM under control of the PAI-1 promoter, CEP promoter, or CAG promoter in vascular endothelial cells. Promoter and human thrombomodulin cDNA sequences (530-2590) coding for the TM molecule were cloned in plasmid pBluescript. To co-express enhanced green fluorescent protein (GFP) as a reporter, the internal ribosome entry site (IRES) sequence and the sequence coding for GFP (Clontech, Palo Alto, CA, USA) were inserted at the 3'end of the thrombomodulin gene sequence. CMV promoter and the LacZ gene sequences between two inverted terminal repeat (ITR) sequences of pW1 were replaced with one of the DNA fragments containing the promoter and the TM gene with or without IRES-GFP sequences to make, pWCEPT, pWCAGT, pWPTIG, and pWCEPTIG. The helper plasmid pIM45, containing rep and cap genes for replication and capsid formation, and pladeno-1 containing E2A, E4, and VA genes of the adnovirus genome were used to produce recombinant AAV vectors as described previously. 36 AAV vector production For viral packaging, 293 cells (a human embryonic kidney cell line) were cultured in DMEM/HAM-F12 (Sigma, St Louis, MO, USA) media in the presence of 10% FBS for transfection. Co-transfection of 293 cells grown in flasks with pIM45, pladeno-1, and one of pWCEPT, pWCAGT, pWPTIG, or pWCEPTIG, was done by a calcium phosphate co-precipitation method as described previously. 36 After 72-h incubation, cells were harvested and lysed by repeated freezing and thawing in Tris-buffered saline (10 mm Tris, 150 mm NaCl) pH 8.0. After DNase I (200 U/ml) treatment at 37°C for 30 min to degrade plasmid DNA, the virus particle containing sample was subjected to two rounds of CsCl-density gradient ultracentrifugation in HEPES-buffered saline pH 7.4 in the presence of 25 mm EDTA at 21°C for 24 h as described. After the first ultracentrifugation, samples were fractionated and analyzed by dot-blot hybridization. Fractionated samples containing virus particles were isolated and subjected to a second CsCl-density gradient ultracentrifugation and samples containing virus particles were isolated as described before. Titration of recombinant AAV2 vectors rAAV2/CEPT, rAAV2/CAGT, rAAV2/PTIG, or rAAV2/CEPTIG, was carried out by quantitative dot-blot hybridization using the 32 P-labeled TM gene as probe. rAAV2/lacZ was also isolated as described. 36 
Transduction of vascular endothelial cells by rAAV2 vectors in vitro
Bovine capillary endothelial cells (BCE) derived from adrenal glands, bovine pulmonary endothelial cells (CPAE), and bovine brain microvascular endothelial cells (BBME) were obtained from ATCC (Rockville, MD, USA), Riken cell bank (Tsukuba, Ibaraki, Japan), and Cell Systems, Kirkland, WA, USA, respectively. Bovine aortic endothelial cells (BAE) and human umbilical vein endothelial cells (HUVEC) were isolated by standard procedures. Except for HUVECs, endothelial cells were cultivated in MEM containing non-essential amino acids, lglutamine, 10% fetal bovine serum (FBS) and seeded in multiwell plates or tissue culture chambers (Chamber Slide; Nunc, Naperville, IL, USA). HUVECs were cultured in medium 199 containing 20% FBS and endothelial cell growth supplement. Endothelial cells were cultured in medium containing rAAV2 vectors at the indicated MOI for various incubation times at 37°C and expression of TM was detected by immunohistochemistry and TM in cell lysates in phosphate-buffered saline containing 0.5% Triton X100 was quantified by an enzyme immunoassay using murine monoclonal antibodies raised against human TM as described. 37 The monoclonal antibodies A60 and A73, generous gifts from Teijin (Tokyo, Japan), used in this study do not cross-react with bovine TM or rodent TM. Expression of GFP was detected by fluorescent microscopy. To quantify GFP expression, endothelial cells transduced by rAAV2/PTIG were removed from culture dishes by 0.05% trypsin, 0.53 mm EDTA solution and subjected to FACS analysis using FACScan (Becton Dickinson, Franklin Lakes, NJ, USA). Expression of β-galactosidase was detected by incubation of cells in buffer containing X-gal as described. 36 Transduction of vascular endothelial cells by rAAV2 vectors in vivo rAAV2/CEPT was injected in the left common carotid artery of Mongolian gerbils under anesthesia by Nembutal. The contralateral carotid artery was temporarily clamped for 5 min after which the clamp was removed and cerebral vascular flow was re-initiated. Gerbils were killed on day 7 after irrigation and fixation with 4% paraformaldehyde and organs were subjected to immunohistochemistry using human TM specific goat polyclonal antibodies (American Diagnostica) to detect human TM expression in vivo. Goat polyclonal antibodies raised against human TM are shown to bind to the first and the second EGF domains of human TM and are specific for the human TM molecule (American Diagnostica). Sections of the brain were incubated in PBS containing human TM-specific goat polyclonal antibodies at 10 g/ml, 10% FBS, 1% casein at 4°C for 16 h after inactivation of internal peroxidase activity by incubation of sections with 4% H 2 O 2 and 0.1% NaN 3 and blocking with 2.5% casein and 50% rabbit serum. After extensive washing, detection of goat antibodies bound to the tissue was carried out using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) followed by incubation with the peroxidase substrate DAB according to the manufacturer's instructions. Nuclear staining was also performed using hematoxylin in some samples.
